CareDx, Inc. (CDNA)

Market Cap	1.03B +22.9%
Revenue (ttm)	412.82M +19.2%
Net Income	-8.19M
EPS	-0.16
Shares Out	51.66M
PE Ratio	n/a
Forward PE	24.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	637,607
Open	20.00
Previous Close	20.49
Day's Range	19.73 - 20.44
52-Week Range	10.96 - 23.24
Beta	2.49
Analysts	Buy
Price Target	28.00 (+40.21%)
Earnings Date	Apr 28, 2026

About CDNA

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about dist...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 17, 2014
• Employees: 765
• Stock Exchange: NASDAQ
• Ticker Symbol: CDNA
• Website: https://caredx.com

Analyst Summary

According to 6 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price target is $28.0, which is an increase of 40.21% from the latest price.

Price Target

$28.0

(40.21% upside)

Analyst Consensus: Buy